Promising drug remibrutinib gets extended safety check in 648 patients

NCT ID NCT07456891

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued treatment with remibrutinib for up to 3 years to people who have already benefited from it in earlier Novartis trials. It aims to collect long-term safety data. About 648 participants with skin or allergy conditions will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Remibrutinib (a drug taken as a tablet)

What this could lead to

If successful, this study could show that remibrutinib is safe and effective for long-term use in skin or allergy conditions.

What could go wrong

This is an open-label roll-over study, not a placebo-controlled trial, so results may be less definitive. Side effects could emerge with longer use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INDICATION OF THE PARENT PROTOCOL

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Sofia, 1421, Bulgaria
Novartis Investigative Site
RECRUITING

Sofia, 1431, Bulgaria
Novartis Investigative Site
RECRUITING

Varna, 9009, Bulgaria
Novartis Investigative Site
RECRUITING

Hamilton, Ontario, L8L 3C3, Canada
Novartis Investigative Site
RECRUITING

London, Ontario, N6H 5L5, Canada
Novartis Investigative Site
RECRUITING

Québec, Quebec, G1V 4W2, Canada
Novartis Investigative Site
RECRUITING

Verdun, Quebec, H4G 3E7, Canada
Novartis Investigative Site
RECRUITING

Brno, 602 00, Czechia
Novartis Investigative Site
RECRUITING

Plzen Bolevec, 32300, Czechia
Novartis Investigative Site
RECRUITING

Prague, 100 34, Czechia
Novartis Investigative Site
RECRUITING

Prague, 150 06, Czechia
Novartis Investigative Site
RECRUITING

Bordeaux, 33075, France
Novartis Investigative Site
RECRUITING

Montpellier, 34295, France
Novartis Investigative Site
RECRUITING

Paris, 75970, France
Novartis Investigative Site
RECRUITING

Rouen, 76031, France
Novartis Investigative Site
RECRUITING

Daegu, Dalseo Gu, 42602, South Korea
Novartis Investigative Site
RECRUITING

Suwon, Gyeonggi-do, 16499, South Korea
Novartis Investigative Site
RECRUITING

Dongjak Gu, Seoul, 07061, South Korea
Novartis Investigative Site
RECRUITING

Gwangju, 61469, South Korea
Novartis Investigative Site
RECRUITING

Incheon, 21565, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03080, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 07441, South Korea
Novartis Investigative Site
RECRUITING

Alicante, 03010, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Madrid, 280796, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain